ライフサイエンスコーパス: malignant lymphoma

1 e according to Revised Response Criteria for Malignant Lymphoma).

2 national Working Group response criteria for malignant lymphoma.

3 sed International Working Group criteria for malignant lymphoma.

4 t in ALK(+) ALCL and possibly other types of malignant lymphoma.

5 fied as monomorphic) and one had a low-grade malignant lymphoma.

6 eas recipients developed polymorphic PTLD or malignant lymphoma.

7 cally confirmed in 8, and 2 others developed malignant lymphoma.

8 one marrow biopsies in the staging of B-cell malignant lymphoma.

9 ucleosis, acquired hypogammaglobulinemia and malignant lymphoma.

10 e extensive enough to suggest a diagnosis of malignant lymphoma.

11 fatal mononucleosis, agammaglobulinemia, or malignant lymphoma.

12 he presence of large-cell diffuse noncleaved malignant lymphoma.

13 erium avii complex (MAC), kaposi sarcoma and malignant lymphoma.

14 e in the development of Kaposi's sarcoma and malignant lymphoma.

15 n occur in a temporary relationship with any malignant lymphoma.

16 mutations in S1PR2 and G(alpha13) occur in a malignant lymphoma.

17 l and posttranscriptional gene expression in malignant lymphomas.

18 ed in a growing number of cancers, including malignant lymphomas.

19 dely used in the management of patients with malignant lymphomas.

20 dal and extranodal diseases in patients with malignant lymphomas.

21 blished mode of therapy in the management of malignant lymphomas.

22 when immunosuppression is halted, to highly malignant lymphomas.

23 ute to pathogenesis in a small percentage of malignant lymphomas.

24 SA-associated clones have not yet evolved to malignant lymphomas.

25 unselected and drug selected cell lines, and malignant lymphomas.

26 nasopharyngeal carcinoma and EBV-associated malignant lymphomas.

27 (CAS) protein in normal lymphoid tissue and malignant lymphomas.

28 erapeutic reagent for the treatment of human malignant lymphomas.

29 siderable promise for the treatment of human malignant lymphomas.

30 lity, and enhancing antibody uptake in human malignant lymphomas.

31 reactive lymphoid hyperplasia to aggressive malignant lymphomas.

32 benign proliferative response to aggressive malignant lymphomas.

33 notype of XLP with hypogammaglobulinemia and malignant lymphoma, a deletion of approximately 250 kb w

34 rotein 1 (MALT1) activity drives survival of malignant lymphomas addicted to chronic B-cell receptor

35 Malignant lymphomas affect patients at any age, with acu

36 erapy had no significant impact on growth of malignant lymphoma after allo-HSCT.

37 svirus may be involved in the development of malignant lymphoma after Kaposi sarcoma in HIV-negative

38 ntrol study of this relation in 80 cats with malignant lymphoma and 114 controls with renal disease d

39 rentiating intrathoracic kaposi sarcoma from malignant lymphoma and opportunistic infections.

40 romal cells function as survival factors for malignant lymphoma and plasmacytoma cells derived from t

41 he effectiveness of therapy in patients with malignant lymphomas and a variety of solid tumors.

42 )) interact to accelerate the development of malignant lymphomas and adenocarcinoma and increase tumo

43 einase-1 (TIMP1) is expressed in a subset of malignant lymphomas and can inhibit tumor spread and pro

44 dose-mortality trends were evaluated for all malignant lymphomas and for non-Hodgkin's lymphoma.

45 (EBV) is associated with the development of malignant lymphomas and lymphoproliferative disorders in

46 T/CT scans in children and young adults with malignant lymphomas and sarcomas.

47 le and female mice (histiocytic sarcomas and malignant lymphomas), and ovary of female mice.

48 cancer, bladder cancer, gall bladder cancer, malignant lymphoma, and lung cancer.

49 c conditions including autoimmune disorders, malignant lymphomas, and immunoregulatory responses to p

50 ormal counterparts of the cells forming this malignant lymphoma are found in the mantle zone of the l

51 Malignant lymphomas are a heterogeneous group of disease

52 Therefore, we recommend that these malignant lymphomas be designated primary effusion lymph

53 abolism pathway have been related to risk of malignant lymphomas, but little is known about their ass

54 protein levels are substantially elevated in malignant lymphoma cells, compared with resting or activ

55 We also show that malignant lymphoma cells, identified by the coexpression

56 We describe the first 2 cases of malignant lymphoma derived from CAR gene-modified T cell

57 tle with BLV-associated lymphocytic leukemia/malignant lymphoma despite viral transcriptional activit

58 age and other factors, the relative risk of malignant lymphoma for cats with any household ETS expos

59 d disease is regarded as a benign condition, malignant lymphoma has been described in association wit

60 atopoietic cells, a direct role of IGF-IR in malignant lymphoma has not been identified.

61 oclonal antibody (MoAb) therapy of the human malignant lymphomas has shown success in clinical trials

62 held at the 11th International Conference on Malignant Lymphomas (ICML) in 2011 concluded that revisi

63 hat passive smoking may increase the risk of malignant lymphoma in cats and that further study of thi

64 held at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland, in June 2011,

65 ntributes to the incidence of GaHV-2-induced malignant lymphoma in the chicken and invites considerat

66 associated herpesvirus in the development of malignant lymphomas in patients negative for the human i

67 nd the uncontrolled CTL expansion leading to malignant lymphomas in severe forms of celiac disease.

68 in six normal lymph nodes or tonsils and 32 malignant lymphomas including five mantle cell, five fol

69 to destructive lymphoepithelial lesions and malignant lymphoma is marked by an increase in transcrip

70 ia and autoimmunity, also predispose mice to malignant lymphomas later in life.

71 shop at the 12th International Conference on Malignant Lymphoma, leading to revised criteria for stag

72 6), a tumor suppressor frequently mutated in malignant lymphomas, leukemias, and prostate cancer, as

73 Specific infections and malignant lymphoma may complicate its clinical course an

74 esults from clinical trials in patients with malignant lymphoma, melanoma, and prostate cancer sugges

75 transformation, abscesses, sarcoidosis), and malignant (lymphoma, metastasis) and its pathological co

76 malignant, 2 reactive); nonimmunodeficiency malignant lymphoma (ML) (7 cases); and sporadic EBV infe

77 IV+ ML (67%); and 3 of 5 nonimmunodeficiency malignant lymphoma (ML, 60%).

78 polymorphic B-cell lymphomas (38%), and five malignant lymphomas/multiple myelomas (71%) exhibited de

79 Final diagnoses included malignant lymphoma (n = 15), polyclonal LPD (n = 8), and

80 del-LMP1 plays a role in the development of malignant lymphomas occurring in immunocompromised patie

81 ntity and should be distinguished from other malignant lymphomas occurring in the body cavities.

82 Feline malignant lymphoma occurs commonly in domestic cats and

83 f spleens from Tat-transgenic mice exhibited malignant lymphoma of B-cell origin.

84 In contrast, methylation analysis of malignant lymphomas of various histologies revealed SOCS

85 the biological categories of hyperplasia and malignant lymphoma, of which only the former can regress

86 the 18 patients with PTLD, 13 had high-grade malignant lymphoma on diagnostic biopsy and received ant

87 untreated controls in adult solid tumor and malignant lymphoma patients was undertaken without langu

88 onal Working Group 2007 revised criteria for malignant lymphoma (peripheral T-cell lymphoma and B-cel

89 issues, unselected cell lines, and untreated malignant lymphoma samples, expression of MDR-1 from bot

90 in drug selected cell lines, and in relapsed malignant lymphoma samples, expression of one allele was

91 ma (PEL) is a recently recognized subtype of malignant lymphoma that exhibits distinctive clinical an

92 only available model is a murine metastatic malignant lymphoma that occurs after intraperitoneal ino

93 nding of the pathogenesis of the most common malignant lymphomas that occur as primary and secondary

94 rately and avoids their confusion with other malignant lymphomas that occur in the body cavities.

95 smoke (ETS) may increase the risk of feline malignant lymphoma, the authors conducted a case-control

96 n of the cancer driver genes BCL2 and MYC in malignant lymphoma thus pointing to a possible new mecha

97 321 for mobilization of PBC in patients with malignant lymphoma was performed.

98 male infertility, and increased frequency of malignant lymphoma were also seen in these hOGG1 TG mice

99 DMBA intragastrically, 70% developed highly malignant lymphomas whereas only 7.5% of CYP1B1-null mic

100 Thirteen patients with malignant lymphoma who were eligible for high-dose thera

101 rall group of 81 children, only the two with malignant lymphoma who were managed with chemotherapy ha

102 s (EBV)-induced lymphoproliferations, and in malignant lymphomas with special reference to those that

103 animals that seroconverted to VCA developed malignant lymphoma within months of inoculation.

104 Malignant lymphomas within inflamed extranodal sites exh